Experimental liver cancer drug shows promise in early trial
Disease control
Terminated
This phase 2 trial tested a drug called Taxoprexin (DHA-paclitaxel) in 13 people with advanced liver cancer that had not responded to prior treatments. The goal was to see if the drug could shrink tumors and how safe it was. The study was terminated early, so results are limited.
Phase: PHASE2 • Sponsor: American Regent, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC